Patents Assigned to Elanco Tiergesundheit AG
-
Patent number: 11938103Abstract: The present invention provides a method of treating liver fluke infections in a mammal in need of such treatment comprising administering an effective amount of diamphenethide in combination with an effective amount of clorsulon.Type: GrantFiled: September 30, 2019Date of Patent: March 26, 2024Assignee: Elanco Tiergesundheit AGInventors: Sarah George, Peter Rolfe, Chouaib Tahtaoui
-
Patent number: 11904008Abstract: Described is a method for the generation of a live vaccine containing stable bacteria carrying at least three attenuating mutations and a vaccine containing bacteria obtained by said method.Type: GrantFiled: August 5, 2020Date of Patent: February 20, 2024Assignee: Elanco Tiergesundheit AGInventors: Klaus Linde, Anke Grosse-Herrenthey
-
Patent number: 11319377Abstract: This disclosure relates to immunogens and monoclonal antibodies useful in the identification and/or treatment of cancer cells, including those of the dog. In one example, chimeric anti-canine CD20 antibodies are provided. The antibodies can be used therapeutically to treat lymphoma in dogs.Type: GrantFiled: August 24, 2017Date of Patent: May 3, 2022Assignee: ELANCO TIERGESUNDHEIT AGInventors: Sarah Rue, Brendan Eckelman, Quinn L. Deveraux, Marc Nasoff
-
Patent number: 10981897Abstract: The present invention provides compounds of the formula: (I) wherein: X is O or S; Q1 and Q2 are independently CR5 or N, provided at least one of Q1 and Q2 is N; Y is a direct bond or CH2; R1 is H, optionally substituted alkyl, alkenyl, alkynyl, cycloalkylalkyl, benzyl or oxetan-3-yl-CH2—; R2 is optionally substituted phenyl, pyridine, pyrimidine, pyrazine or pyridazine; R3 is alkyl or haloalkyl; R4 is optionally substituted pyridine, pyrimidine, pyrazine or pyridazine; R5 is H, alkyl, haloalkyl, cycloalkyl, alkoxy, alkoxyC(O)— or (alkoxy)2CH—; or a salt thereof. The compounds are useful for controlling ectoparasites on animals.Type: GrantFiled: April 30, 2019Date of Patent: April 20, 2021Assignee: Elanco Tiergesundheit AGInventors: Paolo Tosatti, Jean-Yves Wach
-
Patent number: 10874618Abstract: The invention relates to a new fixed dose combination of benazepril with pimobendan.Type: GrantFiled: December 19, 2012Date of Patent: December 29, 2020Assignee: Elanco Tiergesundheit AGInventors: Jernej Grmas, Zdenka Jerala-Strukelj, Sebastjan Reven
-
Patent number: 10828362Abstract: Described is a method for the generation of a live vaccine containing stable bacteria carrying at least three attenuating mutations and a vaccine containing bacteria obtained by said method.Type: GrantFiled: September 5, 2013Date of Patent: November 10, 2020Assignee: Elanco Tiergesundheit AGInventors: Klaus Linde, Anke Grosse-Herrenthey
-
Patent number: 10537549Abstract: The present invention provides a dihydroisoxazole of formula: or a salt thereof, for use in the control of sea lice in fish.Type: GrantFiled: May 3, 2017Date of Patent: January 21, 2020Assignee: Elanco Tiergesundheit AGInventor: Chouaib Tahtaoui
-
Patent number: 10464889Abstract: The present invention relates to a new compound of formula (I) wherein the variables have the meaning as indicated in the claims; or an enantiomer or salt thereof. The compounds of formula (I) are useful in the control of parasites, in particular endoparasites, in and on vertebrates.Type: GrantFiled: July 17, 2018Date of Patent: November 5, 2019Assignee: Elanco Tiergesundheit AGInventors: Noelle Gauvry, Chouaib Tahtaoui
-
Patent number: 10370375Abstract: The invention relates to a compound of formula (I) wherein the variables have the meaning as indicated in the claims; in free form and in salt form; and optionally the enantiomers and geometrical isomers thereof. The compounds of formula (I) are useful as therapeutic agent for organ transplants, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis. Type I diabetes and complications from diabetes, cancer, asthma, atopic dermatitis, autoimmune thyroid disorders, ulcerative colitis, inflammatory bowel diseases, Crohn's disease, Alzheimer's disease, leukemia, osteoarthritis, control of pruritus, chronic respiratory disease or keratoconjunctivitis in mammals.Type: GrantFiled: August 6, 2018Date of Patent: August 6, 2019Assignee: Elanco Tiergesundheit AGInventors: Noelle Gauvry, Chouaib Tahtaoui, Pascal Furet, Pierre Ducray
-
Patent number: 10287276Abstract: The present invention provides compounds of the formula: (I) wherein: X is O or S; Q1 and Q2 are independently CR5 or N, provided at least one of Q1 and Q2 is N; Y is a direct bond or CH2; R1 is H, optionally substituted alkyl, alkenyl, alkynyl, cycloalkylalkyl, benzyl or oxetan-3-yl-CH2—; R2 is optionally substituted phenyl, pyridine, pyrimidine, pyrazine or pyridazine; R3 is alkyl or haloalkyl; R4 is optionally substituted pyridine, pyrimidine, pyrazine or pyridazine; R5 is H, alkyl, haloalkyl, cycloalkyl, alkoxy, alkoxyC(O)— or (alkoxy)2CH—; or a salt thereof. The compounds are useful for controlling ectoparasites on animals.Type: GrantFiled: April 28, 2017Date of Patent: May 14, 2019Assignee: Elanco Tiergesundheit AGInventors: Paolo Tosatti, Jean-Yves Wach
-
Patent number: 10261092Abstract: Compositions and methods for determining immunologically cross-reactive molecules comprising a cross-reactive antigenic determinant are provided, in particular for determining proteins comprising cross-reactive antigenic determinants, in particular for determining proteins that are cross-reactive based on serological screens using sequential immunological challenges to an animal, including determining cross-reactive H. parasuis proteins. Also provided are compositions, vaccines, and kits using the molecules for diagnostics and methods for preventing or treating a disease, disorder, condition, or symptoms thereof associated with infectious agents, in particular infectious microorganisms, in particular for preventing or treating a disease, disorder, condition, or symptom thereof associated with H. parasuis infection.Type: GrantFiled: April 27, 2015Date of Patent: April 16, 2019Assignee: Elanco Tiergesundheit AGInventors: Thomas Plocher, Manuel Campos, Richard Harland, Todd Johnson, Trent Harbison, Dan Keil
-
Patent number: 10059709Abstract: The invention relates to a compound of formula (I) wherein the variables have the meaning as indicated in the claims; in free form and in salt form; and optionally the enantiomers and geometrical isomers thereof. The compounds of formula (I) are useful as therapeutic agent for organ transplants, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis, Type I diabetes and complications from diabetes, cancer, asthma, atopic dermatitis, autoimmune thyroid disorders, ulcerative colitis, inflammatory bowel diseases, Crohn's disease, Alzheimer's disease, leukemia, osteoarthritis, control of pruritus, chronic respiratory disease or keratoconjunctivitis in mammals.Type: GrantFiled: March 25, 2015Date of Patent: August 28, 2018Assignee: Elanco Tiergesundheit AGInventors: Noelle Gauvry, Chouaib Tahtaoui, Pascal Furet, Pierre Ducray
-
Patent number: 10047040Abstract: The present invention relates to a new compound of formula (I) wherein the variables have the meaning as indicated in the claims; or an enantiomer or salt thereof. The compounds of formula (I) are useful in the control of parasites, in particular endoparasites, in and on vertebrates.Type: GrantFiled: August 27, 2015Date of Patent: August 14, 2018Assignee: Elanco Tiergesundheit AGInventors: Noelle Gauvry, Chouaib Tahtaoui
-
Patent number: 10040785Abstract: The present invention concerns compounds of formula (I) or an N-oxide or salt thereof and their use for controlling parasites in and on warm-blooded animals or fish.Type: GrantFiled: February 5, 2018Date of Patent: August 7, 2018Assignee: Elanco Tiergesundheit AGInventors: Noëlle Gauvry, Thomas Goebel, Steve Nanchen, Jean-Luc Perret, Ulrich Roos, Sandra Schorderet Weber
-
Patent number: 10030232Abstract: Disclosed are methods for production of inactivated rotavirus directly from cell culture supernatants containing active or infectious rotavirus (e.g., bovine rotavirus), without prior isolation or purification of the rotavirus from the cell culture supernatants. In some embodiments, inactivated rotavirus (e.g., bovine rotavirus) is produced by heating a volume of culture supernatant to at least a temperature at which the rotavirus is inactivated. In some embodiments, the rotavirus (e.g., bovine rotavirus) is inactivated once the entire volume is heated to at least a temperature at which the rotavirus is inactivated. In some embodiments, the temperature of the cell culture supernatant is maintained for a suitable amount of time, which may be determined using any of the tests described herein. Inactivated rotavirus (e.g., bovine rotavirus) may then be isolated from the culture supernatant.Type: GrantFiled: July 18, 2014Date of Patent: July 24, 2018Assignee: Elanco Tiergesundheit AGInventors: Brent E. Dekker, John M. Herbert, Michael J. Reimnitz
-
Patent number: 9920037Abstract: The present invention concerns compounds of formula (I) or an N-oxide or salt thereof and their use for controlling parasites in and on warm-blooded animals or fish.Type: GrantFiled: November 6, 2015Date of Patent: March 20, 2018Assignee: Elanco Tiergesundheit AGInventors: Noëlle Gauvry, Thomas Goebel, Steve Nanchen, Jean-Luc Perret, Ulrich Roos, Sandra Schorderet Weber
-
Patent number: 9884103Abstract: Disclosed are interactions between different betanodaviruses during infection of cells “in vitro” and in European sea bass. More specifically, fish administered striped jack nervous necrosis viruses (SJNNV), which are then exposed to red-spotted grouper nervous necrosis viruses (RGNNV), have fewer symptoms of disease associated with RGNNV and/or increased survival as compared to fish not administered SJNNV prior to exposure to RGNNV.Type: GrantFiled: May 26, 2014Date of Patent: February 6, 2018Assignee: Elanco Tiergesundheit AGInventors: Juan Jose Borrego, Carlos Carballo Perez, Maria Del Carmen Alonso, Esther Garcia Rosado, Benjamin Lopez-Jimena, Jose F Rodriguez
-
Patent number: 9820488Abstract: The invention relates to compounds of the general formula (I) wherein the variable have the meanings as indicated in the claims, or a physiologically acceptable salt thereof. The active ingredients have advantageous pesticidal properties. They are especially suitable for controlling endoparasites in warm-blooded animals.Type: GrantFiled: November 14, 2014Date of Patent: November 21, 2017Assignee: ELANCO TIERGESUNDHEIT AGInventors: Noëlle Gauvry, François Pautrat
-
Patent number: 9809863Abstract: This disclosure relates to Theiler's disease-associated virus (“TDAV”), reagents relating thereto, and methods for detecting, using, and/or treating diseases associated with TDAV.Type: GrantFiled: October 31, 2013Date of Patent: November 7, 2017Assignees: ELANCO TIERGESUNDHEIT AG, CORNELL UNIVERSITYInventors: Sanjay Chandriani, Peter Skewes-Cox, Amy Kistler, Bud Tennant, Thomas Divers
-
Patent number: 9790280Abstract: This disclosure relates to immunogens and monoclonal antibodies useful in the identification and/or treatment of cancer cells, including those of the dog. In one example, chimeric anti-canine CD20 antibodies are provided. The antibodies can be used therapeutically to treat lymphoma in dogs.Type: GrantFiled: October 25, 2012Date of Patent: October 17, 2017Assignee: Elanco Tiergesundheit AGInventors: Sarah Rue, Brendan Eckelman, Quinn Deveraux, Marc Nasoff